Inflow vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 38)
Inflow logo

Inflow

EmergingHealthcare

General

London ADHD management app with CBT and coaching for adults managing ADHD without relying solely on medication; $16.7M Octopus Ventures Series A with 100K+ downloads competing with Done and Cerebral.

AI VisibilityBeta
Overall Score
D38
Category Rank
#461 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
37
Gemini
40

About

Inflow is a London-based digital health company providing a science-based self-management app for adults with ADHD — backed with $16.7 million raised including an $11 million Series A led by Octopus Ventures in 2023 — delivering cognitive behavioral therapy (CBT), psychoeducation, ADHD coaching, and evidence-based habit management tools through a mobile app that helps adults understand and manage their ADHD without relying exclusively on medication. Founded in 2020, Inflow acquired Lina Health in 2022 to expand telehealth capabilities and has achieved 100,000+ downloads, serving adults who are newly diagnosed, managing ADHD alongside medication, or seeking non-pharmacological coping strategies.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

38
Overall Score
90
#461
Category Rank
#2
81
AI Consensus
83
stable
Trend
stable
36
ChatGPT
92
37
Perplexity
93
40
Gemini
89
39
Claude
96
44
Grok
95

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.